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Abstract
The non-viral gene delivery system is an attractive alternative to cancer therapy. The clinical success of non-viral
gene delivery is hampered by transfection efficiency and tumor targeting, which can be individually overcome by
addition of functional modules such as cell penetration or targeting. Here, we first engineered the multifunctional
gelatin/silica (GS) nanovectors with separately controllable modules, including tumor-targeting aptamer AGRO100,
membrane-destabilizing peptide HA2, and polyethylene glycol (PEG), and then studied their bio-distribution and
in vivo transfection efficiencies by contrast resonance imaging (CRI). The results suggest that the sizes and zeta
potentials of multifunctional gelatin/silica nanovectors were 203–217 nm and 2–8 mV, respectively. Functional
GS-PEG nanoparticles mainly accumulated in the liver and tumor, with the lowest uptake by the heart and brain.
Moreover, the synergistic effects of tumor-targeting aptamer AGRO100 and fusogenic peptide HA2 promoted the
efficient cellular internalization in the tumor site. More importantly, the combined use of AGRO100 and PEG
enhanced tumor gene expression specificity and effectively reduced toxicity in reticuloendothelial system (RES)
organs after intravenous injection. Additionally, low accumulation of GS-PEG was observed in the heart tissues with
high gene expression levels, which could provide opportunities for non-invasive gene therapy.
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Background
Gene delivery to cells can be accomplished by using viral
and non-viral vectors. Regarding safety concerns, the use
of viral vectors has been limited, leading to the evalu-
ation and development of alternative vectors based on
non-viral systems. However, to successfully translate the
use of non-viral vectors from laboratories to clinics, nu-
merous barriers such as transfection efficiency, tumor
targeting, and blood clearance must be overcome to
achieve efficient gene delivery [1]. The barriers can be
individually overcome by the addition of functional
modules such as conjugation of moieties for cell pene-
tration or targeting. Some ligands such as cell-
penetrating peptides Tat, fusogenic peptide HA2, and
folic acid designed or attached to the surface of gene
vectors displayed good intracellular trafficking into tar-
get cells [2–4]. It has been reported that HA2 could in-
fluence macrophage uptake and the distribution of
antisense oligonucleotides (ONs) [5, 6]. Nucleic apta-
mers are potentially well-suited for the therapeutic tar-
geting of drug encapsulated controlled release polymer
particles in a cell- or tissue-specific manner [7, 8]. G-
quadruplex aptamer, AGRO100, can strongly bind to
nucleolin, a multifunctional protein expressed at high
levels in cancer cells [9]. It is currently being evaluated
in phase I clinical trials as the first nucleic acid-based
aptamer for use in cancer treatment in humans. Besides,
modification by a hydrophilic polymer such as polyethyl-
ene glycol (PEG), polyethylene oxide, glucan, and den-
drimer is generally a useful strategy for reducing the
reticuloendothelial system (RES) uptake, thus increasing
the circulation time of administered NP-linked drugs be-
cause nanostructured drugs administered systematically
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can be taken up primarily by the RES through the phago-
cytic pathway [10–13]. PEGylation nanoparticles exhibit
long circulating properties and are preferentially distrib-
uted in tumors [14]. The combination of multiple func-
tional modules into a single nanocarrier can increase the
intracellular delivery of many drugs, genes, and proteins,
which might enhance their therapeutic efficacy [15–17].
Protein-based carriers commonly show low levels of
RES clearance, leading to improved pharmacokinetic
properties [18]. Gelatin, as a natural protein, has excel-
lent biocompatibility and gelification properties. The
strong dependence of gelatin ionization with pH makes
it a competitive candidate for DNA encapsulation [19].
We previously synthesized a series of siloxane cross-
linked gelatin/silica nanovectors (GS NPs) with con-
trolled size and surface charge through a two-step sol–
gel process and investigated their cellular internalization
and transfection efficacy in vitro [20–23]. It was found
that GS NPs are low cytotoxic biomaterials with strong
DNA encapsulation ability as well as considerable trans-
fection efficiency, which was nearly 70 % compared to
the commercial transfection reagent Lipofectamine TM
[20]. Furthermore, the grafting of fusion peptides (Tat,
R8, or HA2) onto GS NPs resulted in a synergistic effect
on cellular internalization and transfection efficacy [22,
23]. These results indicated that these GS NPs have ex-
cellent properties as highly potent and non-toxic intra-
cellular delivery systems, rendering them promising
DNA vehicles to be used as non-viral gene delivery sys-
tems. However, the in vitro and in vivo transfection effi-
ciencies do not always correlate, making the translation
of positive results in cell culture to positive results in
animal studies even more difficult.
Herein, we extended the previous work to the synthe-
sis of a multifunctional gelatin/silica gene delivery sys-
tem with separately controllable functions, including a
polymer matrix for gene stabilization/controlled release,
protein HA2 for cell penetration, aptamer AGRO100 for
tumor targeting, and surface-bound PEG for enhancing
circulatory time. In vitro and in vivo studies were per-
formed to evaluate the effectiveness of this system. Sys-
tematic studies were performed to evaluate the effect of
the surface properties on mediating gene transfection,
which may help in designing functionalized non-viral
vectors in the future.
Methods
Materials
Gelatin (bloom number: 240–270, pH 4.5–5.5) was pur-
chased from Bio Basic Inc. (Amherst, New York, USA).
3-glycidoxypropyl-trimethoxysilane (GPSM) and 3-
aminopropyl-trimethoxysilane (APTMS) were purchased
from Acros Organics (Geel, Belgium). N-succinimidyl 3-
(2-pyridyldithio) propionate (SPDP) was purchased from
Pierce Biotechnology (Waltham, MA, USA). A PEG
polymer of molecular weight 2000 Da with a terminal
amine and carboxylic group (NH2-PEG-COOH) was
purchased from Beijing Kaizheng Biotech Development
Co. Ltd. (Beijing, China). HA2 peptide (GLFGAIAG-
FIENGWEGMIDGC) was provided by Shanghai GL Bio-
chem Ltd. (China). Luciferase plasmid pGL3 and
luciferase assay system were purchased from Promega
(Madison, WI, USA). BCA protein assay kit was ob-
tained from Pierce Biotechnology. Plasmid DNA was
purified using the Qiagen plasmid maxi kits (Hilden,
Germany) according to the manufacturer’s instructions.
The dyes of rhodamine B isothiocyanate (RITC), propi-
dium iodide (PI), and tetramethylrhodamine isothiocyan-
ate (TRITC) as well as DNA aptamer (AGRO100, ggT
ggT ggT ggT TgT ggT ggT ggT ggT TTT TTT TTT TT)
were purchased from Sangon Biotech Co., Ltd. (Shanghai).
All materials used were of analytical grade and used with-
out further purification.
Material Synthesis and Characterization
Amino-functionalized gelatin/silica nanovectors (GS
NPs) were first prepared according to previously re-
ported methods [20]. Total amino group (-NH2) levels
on the surface of GS NPs were quantitatively determined
by using the ninhydrin colorimetric reaction. The
amount was about 0.642 mmol/g. We conjugated RITC
to GS NPs surface based on the reaction between the
isothiocyanate group of RITC and the primary amino
group of GS NPs. RITC (0.3 mg) was added to 50 mg of
GS NPs in pH 8.0 phosphate buffered saline (PBS) and
incubated on a rotator for 2 h at room temperature.
After purification by centrifugation, NH2-PEG-COOH
was linked to the surface of GS NPs by the use of the
coupling reagents, ethyl-3-(dimethylaminopropyl) carbo-
diimide (EDC) and N-hydroxy sulfo-succinimide (NHS).
Twenty milligrams of NHS-activated PEG was dissolved
in 20-mM dimethyl sulfoxide and added to 50 mg of GS
NPs in pH 7.5 PBS. The mixture was incubated for 4 h
at room temperature with mixing to fabricate GS-PEG
NPs. After purification by centrifugation, we further
conjugated the PEG with a heterobifunctional crosslin-
ker (3.3 mg), N-succinimidyl 3-(2-pyridyldithio) propi-
onate (SPDP), via the N-hydroxysuccinimide ester in pH
8.0 PBS for 2 h with mixing. Five OD of sulfhydryl-
containing DNA aptamer (AGRO100) were attached to
this linker via a disulfide bond in pH 8.0 PBS to obtain
the bi-functional GS-PEG-Apt NPs. After purification by
centrifugation, 12 mg of HA2 peptide was linked to the
GS NPs surface by using the coupling reagents, EDC
and NHS, to fabricate the tri-functional GS-HA2/PEG-
Apt NPs.
For transmission electron microscopy (TEM), samples
were prepared by drying one drop of nanoparticle
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suspension in distilled water on carbon-coated copper
grids. Particle size and surface charge were measured by
a Nano-ZS Zetasizer dynamic light scattering detector
(Malvern Instruments, UK). DNA loading of GS NPs
was first accomplished by incubation with the luciferase
plasmid DNA (pGL3) for 1 h at room temperature. The
procedure was as described for synthesis. DNA conden-
sation ability was examined by gel retardation assay, and
DNA retardation was observed by irradiation with a gel
documentation system (Tanon GIS-2008, China).
Cytotoxicity
The cytotoxicity of GS, GS-PEG-Apt, and GS-PEG/
HA2-Apt NPs was evaluated against A549 cells using
MTT assay. Briefly, A549 cells (1 × 104 cells/well) were
seeded in polystyrene 96-well culture plates and incu-
bated for 24 h till the 70 % confluence. The culture
medium was then replaced by 100 μl of serum-free
DMEM medium containing nanoparticles (100–
600 mg/mL). Cells treated with medium only served as
a negative control group. After 24 h co-incubation,
cells were washed with PBS and incubated with 20 μL
of MTT solution (5 mg ml−1 in PBS buffer) for 4 h at
37 °C. Then, MTT solution was removed, and 100 μL
of DMSO was added to dissolve the blue formazan
crystal produced by proliferating cells. The plate was
incubated for additional 30 min before determination
at 570 nm using a spectrophotometric plate reader
(Bio-tek ELX800, USA). All experiments were per-
formed in quadruplicate, and the relative cell viability
(%) was expressed as a percentage relative to the un-
treated control cells.
In Vitro Cellular Uptake Studies
Cellular uptake was quantitatively examined using flow
cytometry. Human lung denocarcinoma A549 cells and
fibroblast 3T3 cells (1.5 × 105 cells/well) were seeded in
12-well plates and cultured overnight in containing 10 %
FBS Roswell Park memorial institute (RPMI) 1640
medium and Dulbecco’s modified Eagle’s medium
(DMEM), respectively. The cells were then treated with
GS NPs/DNA, GS-PEG-Apt NPs/DNA, GS-PEG/HA2-
Apt NPs/DNA-PI, liposome/DNA-PI, or naked DNA-PI
in serum-free RPMI 1640 and serum-free DMEM at 37 °C
for 8 h. A single cell suspension was then prepared by
trypsinization, washed with PBS, and resuspended in ice-
cold PBS. The fluorescent cells with PI incorporated in
NPs were then counted from 10,000 cells by using an
EPICS XL flow cytometer (Beckman Coulter, Brea, CA,
USA) in the FL3 channel. Data analysis was performed
with EPICS XL flow cytometer software, and analytical
gates were chosen as 1 % of control cells falling within the
positive region.
In Vitro and In Vivo Transgene Expression
Prior to the transfection experiments, the optimal Nano-
vector/pDNA weight ratio (N/P ratio) to obtain complexes
that did not form large aggregates was determined by mix-
ing a fixed amount of plasmid with various amounts of
NPs. In general, the transfection complexes were formed
by pipetting an equal volume of plasmids into a NP sus-
pension and mixing rapidly. The final DNA concentration
of the complexes was 200 μg mL−1 for in vivo studies and
10 μg mL−1 for in vitro studies.
For in vitro transfection, A549 cells and 3T3 cells
(1.5 × 105 cells/well) were incubated in triplicate for 16 h
at 37 °C in 5 % CO2 before the addition of the DNA
complexes. The culture medium was then replaced by
1-mL serum-free RPMI 1640 and serum-free DMEM
which contain DNA complexes for 8 h of incubation.
After removing the plasmid complexes, the cells were
post-incubated for 36 h in medium containing serum.
The luciferase expression in cells was quantified with
20 μL of centrifuged lysate supernatant using Luciferase
Assay System according to the manufacturer’s instruc-
tion. Light emission was measured and relative light
units (RLU) mg−1 protein determined by using a FB12
luminometer (Berthold, Germany). Protein concentra-
tion was determined using the PIERCE BCA protein
assay kit according to the manufacturer’s protocol.
For in vivo transfection, the GS-PEG/pGL3, GS-PEG-
Apt/pGL3, and GS-PEG/HA2-Apt/pGL3 NPs were
injected into the tail vein of BALB/c mice at a dose of
50 μg DNA/mouse. Forty-eight hours following i.v. in-
jection, mice were euthanized and major organs (includ-
ing the brain, heart, liver, spleen, lung, and kidney) were
removed and carefully washed with distilled water and
homogenized in 1 mL of lysis reagent using a DY89-II
tissue homogenizer. The homogenate was centrifuged at
14,000g for 20 min at 4 °C. Luciferase activity and cellu-
lar proteins in the supernatant were quantified by a
Luciferase Assay System and the PIERCE BCA pro-
tein assay kit. The results are expressed as light unit
mg−1 protein.
Bio-distribution Studies
Bio-distribution was studied in 6- to 8-week-old nude
mice. The mice were maintained in a specific pathogen
free house. All animal experiments were performed in
compliance with the institutional ethics committee regu-
lations and guidelines on animal welfare. Tumor growth
was monitored daily until it reached the acceptable sizes.
The mice were divided into three groups for passive and
active targeting studies. Two milligrams of RITC-labeled
nanoparticles (GS-PEG, GS-PEG-Apt, and GS-PEG/
HA2-Apt) were dispersed in 100 μL physiological saline
solution and injected into the tail vein. The fluorescence
intensities of the nanoparticle solutions were determined
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before administration to calibrate the TRITC concentra-
tion in the solution. One mouse was injected with an
equal volume of physiological saline solution as a con-
trol. The mice were then anesthetized. Images were ac-
quired by CRi Maestro™ in vivo imaging system. The
excitation wavelength was 555 nm, and emission spectra
were obtained from 500 to 800 nm.
For ex vivo imaging, after in vivo imaging acquisition,
mice were euthanized and major organs were rapidly re-
moved. In addition to direct organ imaging on a non-
fluorescent board, organs were grouped for semiquanti-
tative comparison. Photons emitted from tissues were
quantified as the sum of all detected photon counts from
organs and presented as photons/s using CRi Maestro™
in vivo imaging system.
Results and Discussion
Synthesis and Characterization of Nanoparticles
Various formulation factors and characteristics of nano-
particles could influence their intracellular delivery [24].
Particles with a size of less than 400 nm present with en-
hanced permeability and retention effects, which are ne-
cessary characteristics for accumulation in solid tumor
[25]. Hence, the hydrodynamic diameter and surface
charge of the particles were determined by dynamic light
scattering measurement. The nanocarriers displayed a
well-dispersed spherical structure (Fig. 1). As depicted in
Fig. 2, the size of bare GS was 162.3 ± 0.6 nm, while GS-
PEG-Apt and GS-PEG/HA2-Apt NPs exhibited rela-
tively larger hydrodynamic diameters of 205.6 ± 2.4 nm
and 214.9 ± 2.1 nm, respectively, due to the surface func-
tional layer over the particle. Furthermore, after PEG
grafting, the zeta potential of GS-PEG-Apt and GS-
PEG/HA2-Apt NPs switched to 2.1 and 8.5 mV, respect-
ively, while that of bare GS NPs was +39.6 mV.
The condensation ability of nanoparticles with plasmid
DNA (pDNA) was evaluated by using agarose gel elec-
trophoresis assay. As shown in Fig. 3, free pDNA (lane
2) moved to its usual position, while pDNA was readily
entrapped in the sample holes at an N/P weight ratio of
50–200 (lanes 3 to 8). This complete retardation of the
pDNA demonstrates that GS-PEG-Apt and GS-PEG/
HA2-Apt NPs have strong ability to condense DNA
molecules efficiently and thus can be used for in vitro
gene delivery.
The net surface charge of the nanoparticles also plays
a critical role in the clearance of the nanoparticles from
the animal body due to different adsorption effects on
physiological lipoproteins in the systemic circulation
[26]. Hence, we simply mimicked the body environment
by adding FBS in the culture medium to evaluate the
strength of the nanovectors in the biological environ-
ment. As showed in Fig. 4, naked GS size increased by
12.5 %, while PEG-modified nanoparticles increased by
less than 5 %, exhibiting long serum stability. The pres-
ence of PEG may increase the nanoparticle’s colloidal
stability through steric hindrance and provide non-
fouling properties [27].
Cell Compatibility
The cytotoxicity associated with NPs has always been a
concern in their use as gene vectors for gene therapy. As
shown in Fig. 5, the cell viability is above 80 % for GS,
GS-PEG-Apt, or GS-PEG/HA2-Apt NP groups within
the tested concentration range, and the cytotoxicity ap-
peared dose-dependent. Compared with GS NPs, the
slight decrease of cell viability might be due to the in-
creased inhibition of NF-κB signaling of conjugated
aptamer AGRO100 [9]. Besides, GS-aptamer NPs have a
higher level than our previous peptide-GS NPs [20, 23].
Within the tested concentrations up to 600 mg/mL, the
NPs can be considered comparatively non-cytotoxic.
In Vitro Cellular Uptake and Transgene Expression
In vitro optimization is indispensable to set up effective
delivery systems in vivo. Hence, we first determined
in vitro cellular uptake and transgene expression using
the human lung cancer cell line, A549, as a cancer
model. The in vitro intracellular uptake was quantita-
tively analyzed by FCM using the red emitting PI incor-
porated in NPs as a marker. In vitro transfection
efficiency was determined by assessing the luciferase ac-
tivities in A549 cells and common 3T3 cells, using Lipo-
fectamine (LF) as the positive control. In order to
analyze the tumor targeting efficiency of nanovectors
quantitatively, targeting R was defined as the ratio be-
tween uptake or transfection amount of A549 cancerous
cells and normal cell 3T3.
The different cell uptake percentages resulting from
the differently grafted group and cell types are displayed
in Fig. 6. All nanoparticles showed an optimized cell up-
take by the A549 cells compared with 3T3 cells, espe-
cially GS-PEG-Apt and GS-PEG/HA2-Apt presented a
five- to tenfold increased uptake due to a receptor-
mediated targeting to A549 cell. The increased uptake
amount indicates that the peptide-GS nanocarrier in-
ternalization is not influenced by surface adsorption.
Moreover, the modification with aptamer and HA2 (GS-
PEG/HA2-Apt) could enhance the cellular uptake by
15–73 % in comparison with GS-PEG-Apt, which is due
to the fact that induced HA2 peptide mediates cell
membrane destabilization, further enhancing endosomal
escape and increasing cellular distribution [28]. More-
over, the uptake targeting ratio of the bi-functional GS-
PEG-Apt was the highest (2.97), followed by GS-PEG/
HA2-Apt (1.98) and GS-PEG (1.65).
The transfection efficiency of three nanovectors (GS-
NPs, GS-PEG-Apt, and GS-PEG/HA2-Apt) in two N/P
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ratios (100 and 200) is presented in Fig. 7. The expres-
sion levels of pGL3 delivered by cationic GS and DNA
electrostatic complexes were low and similar in both cell
types due to their accumulation at the nuclear mem-
brane after cellular internalization. GS-PEG-Apt and
GS-PEG/HA2-Apt enhanced gene expression by three-
to ninefold over GS NPs and naked DNA, inferring that
aptamer AGRO100 increased the transfection efficiency.
Especially, after optimization via AGRO100 and HA2,
GS-PEG/HA2-Apt in each cell line exhibited a
Fig. 1 Schematics and TEM images of GS nanoparticles coated with PEG (a), nanoparticles coated with PEG and aptamer (b), and nanoparticles
coated with PEG, HA2 peptide, and aptamer (c)
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synergistic effect on transfection efficiency. Besides, the
expression levels of pGL3 delivered by GS-PEG-Apt and
GS-PEG/HA2-Apt NPs in A549 cells were two to three
times higher compared to that in the common 3T3 cells,
demonstrating that the aptamer AGRO10 modification
enhanced the transfection efficiency by generating a tar-
geting effect. In addition, the tri-functional GS-PEG/
HA2-Apt presented a higher relative transfection ratio R
(2.21) than GS-PEG-Apt (2.13) when the N/P ratio was
200:1, but this was reversed at a N/P ratio of 100:1,
which may be explained by a lower cellular uptake tar-
geting of GS-PEG/HA2-Apt NPs.
In Vivo Bio-distribution and Gene Expression
The therapeutic efficiency of a vector does rely not only
on its intrinsic activity but also on transfection effi-
ciency at the targeted site. In this study, a heterobifunc-
tional PEG was employed for conjugation of aptamer
AGRO100, taking advantage of PEG’s potential to
minimize binding to plasma proteins, thus reaching
tumor cells. Additionally, HA2 was introduced to im-
prove the transfection efficiency of nanoparticles
in vivo. Thus far, there is no report of in vivo tumor tar-
geting of multifunctional GS nanovectors via intraven-
ous injection.
Fig. 3 Gel electrophoresis assay of NP/DNA complexes. Lane 1:
marker; Lane 2: naked DNA (ND); Lanes 3–4: GS/DNA complexes; Lanes
5–6: GS-PEG-Apt/DNA complexes; Lanes 7–8: GS-PEG/HA2-Apt/DNA
complexes. Complexes with GS/DNA weight ratio of 200 (lanes 3, 5,
and 7) and 100 (lanes 4, 6, and 8) were investigated in deionized water
Fig. 4 Hydrodynamic size changes of the GS coated with PEG,
aptamer, and HA2 peptide incubated in PBS plus 10 % FBS at 37 °C
for 24 h
Fig. 2 Size and surface charge of GS, GS-PEG-Apt, and
GS-PEG/HA2-Apt NPs
Fig. 5 Normalized dose-response for cell viability of GS, GS-PEG-Apt,
and GS-PEG/HA2-Apt NPs by MTT assay. Bars represent the
corresponding standard deviations (n = 6)
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Bio-distribution and Tumor Targeting
One major pitfall of in vitro studies is that they cannot
be reproduced in vivo. GS-PEG, GS-PEG-Apt, and GS-
PEG/HA2-Apt NPs were labeled with RITC, and 2 mg/
mouse was intravenously administrated into A549
tumor-bearing mice. As shown in Fig. 8, our NPs accu-
mulated dominantly in highly perfused organs such as
the liver and spleen. Moreover, the uptake of GS-PEG/
HA2-Apt NPs in tumor sites was most obvious, followed
by GS-PEG-Apt and GS-PEG during 90 min. This
phenomenon might be due to the fact that the surface
coverage of NPs altered the characteristics of their distri-
bution in vivo [29]. Firstly, PEGylation could endow NPs
a hydrophilic protective layer to repel the protein ab-
sorption, further reducing NPs elimination by the RES.
Thus, the NPs possessed a good passive targeting effect.
Correspondingly, three PEG-functional NPs were
present in tumors at 60 and 90 min after injection. Sec-
ondly, aptamer AGRO 100 on the surface of the NPs
could be recognized and bound with nucleolin-positive
A549 tumor cells, later resulting in an increased level of
intracellular delivery of NPs to the tumor site. Hence,
modifying AGRO 100 on the NPs endows them with
tumor-targeting specificity. Thus, more GS-PEG-Apt
and GS-PEG/HA2-Apt were found in tumors (Fig. 8).
Thirdly, HA2 peptide DNA could help NPs escape
quickly from the endosome, improving the efficiency of
tumor uptake.
To further investigate the distribution of the three
types of surface-modified NPs in various organs, the ani-
mals were euthanized immediately after intravenous in-
jection of GS-PEG, GS-PEG-Apt, and GS-PEG/HA2-
Apt at the 90-min time point, and signal intensity from
the dissected tissues was quantified as the sum of all de-
tected photon counts per second within the region of
interest. As shown in Fig. 9, more than 60 % of nanopar-
ticles mainly accumulated in RES organs (the liver, lung,
and spleen) due to a higher circulating blood passing
and small quantities (1.5–2.1 %) were detected in the
brain and heart. The overall amounts of NPs in tissues
were in the order of liver > tumor > kidney, spleen,
lung ≥ heart, brain. These observations corroborated the
results that the PEG coverage leads to an improved sys-
temic distribution and to the lighting of the most vascu-
larized areas such as the lower limb and liver, which
permanently shelters about 10 % of the total blood [29,
30]. Moreover, the accumulation of GS-PEG-Apt and
GS-PEG/HA2-Apt in tumor significantly increased by
25.7 and 78.8 %, respectively, when compared with bare
GS-PEG (Fig. 9). The high tumor accumulation resulted
from the long blood circulation time, the specific high
tumor-binding affinity of AGRO 100-functionalized NPs,
and the synergistic effect of HA2 and AGRO 100. Add-
itionally, it is interesting to note that, at 90 min, the
maximum accumulation of GS-PEG-Apt in the liver was
only about half of the other two NPs. This may be attrib-
uted to the combined effect of good tumor targeting of
AGRO 100 and the relatively higher number of PEG
molecules with flexibility, leading to the lower stealthi-
ness to the RES organs.
Quantitative In Vivo Gene Expression
Using GS-PEG/pGL3, GS-PEG-Apt/pGL3, and GS-PEG/
HA2-Apt/pGL3 complexes for in vivo transfection ex-
periments, the transfection efficiencies in the principal
organs were measured at 48 h after intravenous injection
(Fig. 10). The amount of pGL3 used was 50 μg/mouse.
The luciferase expression of the GS-PEG-Apt/pGL3 and
GS-PEG/HA2-Apt/pGL3 NPs in the excised tumors was
86 and 89 U mg−1 protein, respectively, about threefold
Fig. 7 Efficiency of nanoparticle (GS, GS-PEG-Apt, and GS-PEG/HA2-
Apt)-mediated in vitro transfection of luciferase plasmid pGL3
Fig. 6 Cellular uptake of PI by A549 and 3T3 cells incubated with
DNA-PE, GS/DNA-PE, GS-PEG-Apt/DNA-PI, and GS-PEG/HA2-Apt/
DNA-PI NPs for 4 h, as determined by flow cytometry
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higher than that of the GS-PEG/pGL3 NPs (34 U mg−1
protein). Furthermore, relatively low luciferase expres-
sion of GS-PEG-Apt/pGL3 and GS-PEG/HA2-Apt/
pGL3 NPs was recorded in the brain, heart, and liver
when compared with that of GS-PEG/pGL3, whereas
the spleen and kidney levels did not markedly changed.
Interestingly, in vivo transfection efficiencies of the three
nanovectors were inconsistent in their bio-distribution
due to tissue-specific differences. This finding demon-
strates that the modification of tumor-targeting moieties
might be necessary to increase tumor gene expression
specificity, and incorporating PEG could effectively re-
duce toxicity in RES organs after intravenous injection.
For all three types of NPs, gene expression in the heart
was the highest (33 % in all), which raises a concern re-
garding cardiovascular diseases, and provides some op-
portunities for non-invasive gene therapy for specific
diseases such as heart failure.
Conclusions
The clinical application of designed non-virus gene car-
riers is impeded by inconsistent efficacy in vitro and
in vivo. In this study, a gelatin/silica gene delivery system
optimized via functional modules (tumor-targeting apta-
mer AGRO 100, HA2, and PEG) was developed and
evaluated for effectiveness in vitro and in vivo. The re-
sults demonstrated that the synergistic effects of AGRO
100 and fusogenic peptide HA2 as well as PEG could ef-
ficiently promote cellular internalization, in vitro trans-
fection activity, and tumor targeting. However, the
modification of aptamer AGRO 100 and PEG might be
necessary to increase tumor gene expression specificity
and to effectively reduce toxicity in RES organs after
intravenous injection. Moreover, we observed a low ac-
cumulation of GS-PEG in the heart tissues with high
gene expression levels, which could provide some oppor-
tunities for non-invasive gene therapy.
Fig. 9 Semiquantitative bio-distribution of GS-PEG, GS-PEG-Apt, and
GS-PEG/HA2-Apt NPs in nude mice determined by the averaged
fluorescence intensity of the main organs
Fig. 10 Quantitative evaluation of gene expression in vivo.
Luciferase expression 48 h after administration of GS-PEG/DNA,
GS-PEG-Apt/DNA, and GS-PEG/HA2-Apt NPs into BALB/c mice at a
dose of 50 μg/mouse
Fig. 8 a In vivo fluorescence images of A549 tumor-bearing BALB/c mice at different time points post tail-vein injection of rhodamine-labeled
GS-PEG, GS-PEG-Apt, and GS-PEG/HA2-Apt NPs. b Ex vivo fluorescence images of excised organs at 1.5 h post tail-vein injection
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